Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer
David M. O’Malley, Tashanna Myers, Pauline Wimberger, Toon Van Gorp, Andrés Redondo, David Cibula, Shibani Nicum, Manuel Rodrigues, Floor Backes, Joyce N. Barlin, Sharyn N. Lewin, Peter Lim, Bhavana Pothuri, Elisabeth Diver, Susana Banerjee, Domenica Lorusso
Abstract
At first recurrence, platinum-sensitive ovarian cancer (PSOC) is frequently treated with platinum-based chemotherapy doublets plus bevacizumab, then single-agent bevacizumab. Most patients' disease progresses within a year after chemotherapy, emphasizing the need for novel strategies. Mirvetuximab soravtansine-gynx (MIRV), an antibody–drug conjugate, comprises a folate receptor alpha (FRα)-binding antibody and tubulin-targeting payload (maytansinoid DM4). In FRα-high PSOC, MIRV plus bevacizumab previously showed promising efficacy (objective response rate, 69% [95% CI: 41–89]; median progression-free survival, 13.3 months [95% CI: 8.3–18.3]; median duration of response, 12.9 months [95% CI: 6.5–15.7]) and safety. The Phase III randomized GLORIOSA trial will evaluate MIRV plus bevacizumab vs. bevacizumab alone as maintenance therapy in patients with FRα-high PSOC who did not have disease progression following second-line platinum-based doublet chemotherapy plus bevacizumab.Clinical Trial Registration: ClinicalTrials.gov ID: NCT05445778; GOG.org ID: GOG-3078; ENGOT.ESGO.org ID: ENGOT-ov76